Moneycontrol Be a Pro
Get App
SENSEX NIFTY
Ind-Swift Laboratories > Company History > Pharmaceuticals > Company History of Ind-Swift Laboratories - BSE: 532305, NSE: INDSWFTLAB
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > COMPANY BACKGROUND - Ind-Swift Laboratories

Ind-Swift Laboratories

BSE: 532305|NSE: INDSWFTLAB|ISIN: INE915B01019|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Dec 13, 10:24
25.00
0.7 (2.88%)
VOLUME 5,150
LIVE
NSE
Dec 13, 10:19
24.65
0.5 (2.07%)
VOLUME 15,887
Company History - Ind-Swift Laboratories
YEAR                                              EVENTS
 
 2000 - The Company has developed a new drug ASTROVASTATIN which it
 would
              be launching in both domestic and international market.
 
           - The Company has alloted 7,43,300 -- five per cent
 non-cumulative, redeemable
              preference shares of Rs. 00 each at par to promoters
 group and associates.
 
           - The Unit Trust of India has picked up 5,00,000 No. of
 equity shares of the
              company which account for 4.98 per cent of the issued
 equity capital of the company.
 
           - The Company has entered into exclusive marketing
 agreements with some major
              international pharma companies.
 
           - Ind Swift Labs, a Chandigarh-based pharmaceutical
 company, has entered into 
             agreement with eight international pharmaceutical
 companies to source their 
            requirements for Clarithromycin, Fexofenadine,
 Roxithromycin and Candesartan 
            from the company.
 
 2002-Ind-Swift Laboratories Ltd has informed BSE that in the Board
 Meeting held on 30th July 2002 the Board has forfeited 1,75,900
 equity shares on which allotment money was due since 19th July,
 1997.
 
 2003
 the board has  approved the issue of 2322750 Equity shares upon
 conversion of preference shares into equity shares capital to the
 followings: -
 
 1. 1870375 equity shares to promoters at the rate of Rs 32/- per
 share 
 2. 452375 equity share to other bodies corporate at the rate of Rs
 32/- per share.
 
 -Ind-Swift Laboratories Ltd. has informed that the company has
 received an intimation from Ind-Swift Ltd., the promoter company that
 it has disinvested 386930 equity shares (2.48%) of the company and the
 present holding of Ind-Swift Limited is 22,57,970 equity shares of Rs.
 10/- each (14.46%).
 
 2004
 
 -Sets up subsidiary in US
 
 - Ind-Swift Laboratories shifts corporate and head office from SCO
 813, Shivalik Enclave, Nac, Manimajra, Chandigarh - 160101 to SCO
 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160101
 
 - Ind Swift Laboratories Ltd gets achievement award for the Best
 Performing Company in Category E by the Express Pharma Pulse for the
 year 2004.
 
 -Ind Swift Laboratories enters into long term agreements for supply
 of APIs
 
 -Ind Swift Laboratories wins Deloitte Fast 500 Award 2004 in
 HongKong
 
 2005
 
 - Ind Swift Laboratories puts three new units to operation.
 
 - The Company has recommended a dividend of 15%.
 
 2006
 
 - Ind Swift Laboratories inaugurates its state of art R&D centre.
 
 - Ind-Swift Labs opens R&D centre in Mohali.
 
 - The Company has recommended a Dividend of 15% (Rs 1.50 per Share)
 on the equity shares of the Company and Re 1/- per share on the
 preference shares of the Company.
 
 - Chandigarh-based Ind Swift Laboratories Ltd has got the Bhartiya
 Udyog Rattan Award for its contribution to society and national
 development, given by the National Education and Human Resource
 Development Organisation, a national social charitable organisation
 for National development, last week in Mumbai. Maharashtra Education
 Minister Vasant Purake gave the award to O P Thapliyal, HR head of
 the company.
 
 2007
 
 - Ind Swift Laboratories Ltd has informed that the Company has
 successfully completed USFDA inspection for Clarithromycin, Active
 Pharmaceutical Ingredient (API) manufacturing facility. Ind-Swift
 Laboratories Inc USA (ISL INC.), a wholly owned subsidiary of the
 Company was instrumental in achieving this milestone, said N R
 Munjal, Managing Director.
 
 - The Company at its meeting held on July 30, 2007, inter alia, has
 recommended a dividend of 10% on the Equity Shares of the Company.
 
 2008
 
 - The Board has recommended a dividend of 10% on the Equity Shares of
 the Company.
 
 - Ind-Swift Laboratories Ltd - Change in Board of Directors
 1) Sh. S.R. Mehta has been nominated as the Chairman of the Company.
 
 2) Sh. N.R. Munjal has been nominated as the Vice-Chairman of the
 Company.
 3) Sh. V.K. Mehta has been nominated as the Managing Director of the
 Company. 
 
 -Registered Office of the Company has been shifted From SC0 493-94,
 Sector 35-C, Chandigarh - 166022 To SCO 850, Shivalik Enclave ,NAC,
 Manimajra, Chandigarh - 160101.
 
 2009
 
 - The Board has recommended a dividend of 10% on the Equity Shares of
 the Company.
 
 - The Company at its meeting held on March 24, 2009, have appointed
 the following as Independent Directors with immediate effect: 1. Mr.
 H P S Chawla 2. Mr. N D Aggarwal. 3. Mrs. Nirmal Aggarwal.
 
 2010
 
 - The Board recommended a dividend of Rs. 1/ per share of Rs. 10/-
 each.
 
 - Ind-Swift Laboratories Ltd has informed BSE that the Board of
 Directors have appointed Dr. N. P. Singh as Independent Director with
 immediate effect.
 
 2011
 
 - Ind-Swift Laboratories Ltd has informed BSE regarding a Press
 Release dated September 23, 2011 titled  Ind-Swift Laboratories gets
 TGA approval from Australia for its seven APIs.
 
 - Ind-Swift Laboratories Ltd has informed BSE  regarding a Press
 Release titled Ind-Swift Labs files two more DMFS with USFDA.
 
 - The Board has recommended a dividend of Rs 1/- per share on Equity
 Shares of Rs.10/- each the Company.
 
 - nd-Swift Laboratories Ltd has informed BSE regarding a Press
 Release dated February 17, 2011 titled Ind-Swift Laboratories gets
 PMDA Approval for Pioglitazone and Risedronate Sodium from Govt of
 Japan.
 
 2012
 
 - Ind-Swift Laboratories Ltd has informed BSE regarding a Press
 Release titled Ind Swift Labs Bags First Order for Contract
 Research.
 
 - Ind-Swift Laboratories Ltd has informed BSE regarding a Press
 Release dated April 10, 2012 titled Ind-Swift Labs gets USFDA for 5
 APIs for its Derabassi facility.
 
 - Ind-swift, one of the leading pharmaceutical companies in India,
 known for its drug research and development, yesterday, announced
 that it has launched the generic formulations of the drug
 Atorvastatin in UK, in collaboration with Wockhardt UK Ltd., a
 pharmaceutical and biotechnology company.
 
 - Buoyed by the launching of Atorvastatin Tablets in UK, shares of
 drug making company Ind-Swift Ltd gained over 2 per cent on the
 Bombay Stock Exchange in early trading.
 
 2013
 
 -R K Ummat has been appointed as an Independent Director on the Board
 of the Company.
 
 2014
 
 -Dr. Vinay Kumar Arora has been appointed as an Independent Director
 w.e.f. March 31, 2014.
 
 
 
Source : Dion Global Solutions Limited
Quick Links for Ind-Swift Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.